TLX-66 is a monoclonal antibody conjugated commercialized by Telix Pharmaceuticals, with a leading Phase I program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of TLX-66’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for TLX-66 is expected to reach an annual total of $8 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TLX-66 Overview

TLX-66 is under development for the treatment of acute myeloid leukemia, acute lymphoblastic leukemia, juvenile myelomonocytic leukemia (JMML), refractory acute myeloid leukemia and hematopoietic stem cell transplantation. It is administered as intravenous infusion. The drug candidate constitutes murine IgG1 monoclonal antibody BW250/183 labeled with yttrium Y 90. It acts by targeting CD66b expressing cancer cells.

It was also under development for myelodysplasia, multiple myeloma, chronic myeloid leukemia and systemic AL amyloidosis.

Telix Pharmaceuticals Overview

Telix Pharmaceuticals (Telix) is a biopharmaceutical company that develops and commercializes radiopharmaceuticals to detect and treat cancer. It offers Illuccix, an imaging agent targeting men with prostate cancer. The company is investigating TLX250-CDx (companion diagnostic) an imaging agent to diagnose renal cancer using positron emission tomography (PET); and TLX250, a radiopharmaceutical therapy against renal cancer. Telix is also evaluating TLX591, an antibody-based therapeutic radiopharmaceutical to treat prostate cancer; TLX101 drug for the treatment of glioblastoma (GBM); and TLX66-CDx and TLX66 programs for bone marrow conditioning. It utilizes molecularly-targeted radiation (MTR) technology, where a radionuclide is attached to a targeting small molecule or antibody that binds to tumor cells and destroys them. The company operates in the US, Japan, and Belgium. Telix is headquartered in Melbourne, Victoria, Australia.

The company reported revenues of (Australian Dollars) AUD7.6 million for the fiscal year ended December 2021 (FY2021), an increase of 45.7% over FY2020. The operating loss of the company was AUD75.3 million in FY2021, compared to an operating loss of AUD46.8 million in FY2020. The net loss of the company was AUD80.5 million in FY2021, compared to a net loss of AUD44.9 million in FY2020.

For a complete picture of TLX-66’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.